narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Patient Education

Patient Education

Patient Education

  • Educate the patients regarding their condition & its implications at the time of diagnosis
  • Regular consultation between the patient & physician is essential to help patients modify their lifestyle & provide optimal management
  • Family support can also improve the course of the disease by helping the patients overcome challenges
  • Inform family members, friends, & co-workers of the signs of narcoleptic spells to help patients lessen possible injuries
  • Advise patients on their activities & jobs
    • Avoid potentially dangerous activities such as operating motor vehicles & machines when feeling sleepy
    • Avoid shift-work, driving, transportation-related jobs, or any work which requires continuous attention for long hours with breaks

Adequate & Regular Nocturnal Sleep

  • Patient should have adequate & regular nocturnal sleep to avoid exacerbating excessive daytime sleepiness
  • Comply with a strict sleep schedule of at least 7-8 hours of sleep at night with a consistent bedtime & time of morning awakening
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Jun 2020
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Roshini Claire Anthony, 19 Oct 2020

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.